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Summary
 
Cellular immune hyporesponsiveness can be induced by the presentation of soluble protein an-
tigens to mucosal surfaces. Most studies of mucosa-mediated tolerance have used the oral route
of antigen delivery and few have examined autoantigens in natural models of autoimmune dis-
ease. Insulin is an autoantigen in humans and nonobese diabetic (NOD) mice with insulin-
dependent diabetes mellitus (IDDM). When we administered insulin aerosol to NOD mice af-
ter the onset of subclinical disease, pancreatic islet pathology and diabetes incidence were both
significantly reduced. Insulin-treated mice had increased circulating antibodies to insulin, ab-
sent splenocyte proliferation to the major epitope, insulin B chain amino acids 9–23, which
was associated with increased IL-4 and particularly IL-10 secretion, and reduced proliferation
to glutamic acid decarboxylase, another islet autoantigen. The ability of splenocytes from insu-
lin-treated mice to suppress the adoptive transfer of diabetes to nondiabetic mice by T cells of
diabetic mice was shown to be caused by small numbers of CD8 
 
gd
 
 T cells. These findings re-
veal a novel mechanism for suppressing cell-mediated autoimmune disease. Induction of regu-
latory CD8 
 
gd
 
 T cells by aerosol insulin is a therapeutic strategy with implications for the pre-
vention of human IDDM.
 
I
 
nsulin-dependent diabetes mellitus (IDDM)
 
1
 
 results from
the selective destruction of insulin-producing 
 
b
 
 cells in
the islets of the pancreas, within an autoimmune inflamma-
tory “insulitis” lesion (1, 2). The primary role of autoreac-
tive T cells in mediating 
 
b
 
 cell destruction has been shown
directly in two spontaneous animal models of IDDM, the
Bio-Breeding (3) rat and the nonobese diabetic (NOD) mouse
(4). Target autoantigens that trigger or drive immune reac-
tivity to 
 
b
 
 cells not only have diagnostic applications, but
are potential agents for specific immunotherapy (5–8). Sev-
eral potentially pathogenic islet/
 
b
 
 cell autoantigens have
been identified by their reactivity with circulating antibod-
ies or T cells in rodents and humans with subclinical or
clinical IDDM, particularly insulin, glutamic acid decar-
boxylase (GAD), and a tyrosine phosphatase, IA-2 (9). In-
sulin and its precursor, proinsulin, however, are the only
IDDM autoantigens that are 
 
b
 
 cell specific. Insulin autoan-
tibodies are a risk marker for the development of clinical
IDDM (10) and have been detected before autoantibodies
to other islet antigens in the offspring of diabetic mothers
(11). Increased proliferation of peripheral blood T cells to
human insulin can be demonstrated in up to half of sub-
clinical and recently diagnosed IDDM subjects (12), but re-
sponses are relatively low. This is possibly because the
dominant human T cell epitope is in proinsulin; a peptide
that spans the natural cleavage site between the B chain of
insulin and the connecting (C) peptide in proinsulin elicits
T cell proliferation in a majority of subclinical subjects (13).
In the NOD mouse, insulin autoantibodies are reported to
be a risk marker for the development of diabetes (14) and
the majority of T cell clones generated from the insulitis le-
sion react to the insulin B chain, amino acids 9–23 (15).
An autoantigen can be assumed to be pathogenic if its
administration modifies the natural history of autoimmune
disease. Autoantigen-specific strategies of immune toler-
ance induction have been shown to favorably modify the
natural history of experimental autoimmune disease in ro-
dents (5–8, 16). The presentation of soluble protein antigen
to mucosal surfaces, classically via the oral route, results in
selective suppression of antigen-specific, T cell–mediated,
delayed-type hypersensitivity (DTH) and IgE responses
(16–18). “Oral tolerance” has been associated with the de-
viation of immunity away from T cell (Th1) to antibody
(Th2) responses, with the induction of regulatory T cells
and, at higher antigen doses, with both T cell anergy and T
cell deletion (16, 19). Despite widespread interest in the
possibility of preventing IDDM, relatively few studies have
 
1
 
Abbreviations used in this paper:
 
 DTH, delayed-type hypersensitivity;
GAD, glutamic acid decarboxylase; IDDM, insulin-dependent diabetes
mellitus; NOD, nonobese diabetic (mice).
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evaluated mucosa-mediated tolerance in the natural NOD
mouse model. Zhang et al. (20) found that oral porcine in-
sulin (1 mg twice weekly) delayed the onset and reduced
the incidence of diabetes, and was associated with splenic
T cells that partially blocked the transfer of diabetes to
young NOD mice by spleen cells from diabetic mice. Sub-
sequently, Bergerot et al. (21) reported that the regulatory
cells induced by oral insulin were CD4
 
1
 
 T cells. In studies
of oral tolerance to guinea pig myelin basic protein in the
Lewis rat model of experimental autoimmune encephalo-
myelitis (reviewed in reference 16), however, both CD4
 
1
 
and CD8
 
1
 
 regulatory T cells that secrete IL-4, IL-10,
TGF-
 
b
 
, or TGF-
 
b
 
, respectively, have been described. Daniel
and Wegmann (15) recently reported that intranasal admin-
istration of insulin B chain amino acids 9–23 protected
NOD mice from diabetes, but did not define a mechanism;
Tian et al. (22) reported that a single intranasal dose of
GAD T cell epitope peptides given to NOD mice before
the onset of insulitis induced the deviation of antiislet immu-
nity towards Th2 responses and reduced diabetes incidence,
in association with regulatory CD4, not CD8, T cells.
Holt and co-workers described the suppression of T cell
and IgE responses to OVA after its inhalation in rats or
mice, which was transferable by CD8
 
1
 
 T cells (18) and was
subsequently found to be effected by small numbers of
OVA-specific CD8 
 
gd
 
 T cells (23). There is increasing ev-
idence for the immunoregulatory role of 
 
gd
 
 T cells in gen-
eral (24–29). We therefore decided to investigate the effect
of aerosol insulin inhalation in the NOD mouse. This
mode of delivery of autoantigen to the nasopharyngeal and
upper bronchial mucosa could have advantages over oral
insulin in humans. It is convenient and direct, might re-
quire a smaller dose, and be less likely to be associated with
insulin degradation and variability of absorption. In partic-
ular, we wished to determine if aerosol insulin would be
therapeutic if given after the onset of insulitis and to define
the nature of the regulatory cells that it might potentially
induce.
 
Materials and Methods
 
Aerosol Treatment and Diabetes Assessment.
 
Semisealed boxes of
eight female NOD mice were each aerosolized by connection to
a standard patient electric pump (Maymed Aerosol MKV; Anaes-
thetic Supplies, Sydney, Australia) and an Aeroflo nebulizer
(Waite & Co., Sydney, Australia). Recombinant human insulin
(Humulin R; Aza Research, West Ryde, Australia) or control
OVA protein, at 4 mg/ml, was delivered over 10 min at an air
flow rate of 6 liters/min in a rated droplet size of 
 
,
 
5.8 
 
m
 
m, to
groups of 24–32 mice. All treatments were given between 0900
and 1100 h. Protocols and mouse care were approved and super-
vised by the institutional Animal Ethics Committee. Retroorbital
venous blood was sampled at least every 28 d from 100 d of age,
and mice were considered diabetic if their blood glucose, con-
firmed by a repeat test, was 
 
.
 
11 mM. Glucose was measured
with BM-Test Glycemie
 
Ò
 
 strips and a Reflolux
 
Ò
 
 II meter (Boeh-
ringer Mannheim GmbH, Mannheim, Germany) on a drop of
blood aspirated via a glass capillary tube from the retroorbital
venous plexus of unanesthetised mice.
 
Histology.
 
Mice were killed by CO
 
2
 
 inhalation, and the pan-
creas and salivary glands were immediately removed into Bouin’s
fixative and embedded in paraffin. The insulitis score, a measure
of the severity of islet infiltration, was determined blindly by two
independent investigators by grading and then averaging a mini-
mum of 15 separate islets in serial 6-
 
m
 
m pancreas sections stained
with hematoxylin and eosin. The grading scale was as follows: 0,
no infiltration, islet intact; 1, 
 
,
 
10 periislet lymphoid cells, islet
intact; 2, 10–20 peri- and intraislet lymphoid cells, islet intact; 3,
 
.
 
20 peri- and intraislet lymphoid cells, 
 
,
 
50% of islet replaced or
destroyed; 4, massive lymphoid infiltrate with 
 
.
 
50% of islet re-
placed or destroyed. Infiltration of the salivary glands was graded
by the number of lymphoid cells in clusters: 0, no cells; 1, 
 
,
 
10
cells; 2, 10–50 cells; 3, 
 
.
 
50 cells.
 
Immune Responses.
 
Spleen cells from individual normoglyce-
mic mice were treated with a red cell lysis buffer, resuspended,
and incubated in quadruplicate at 2 
 
3
 
 10
 
5
 
/200 
 
m
 
l of serum-free
HL-1 medium (Hycor, Portland, ME) containing 50 
 
m
 
m 2-MER
in round-bottom wells with the indicated concentrations of anti-
gen. After 3 d at 37
 
8
 
C in 5% CO
 
2
 
/air, 100-
 
m
 
l aliquots from each
replicate supernatant were collected and stored at 
 
2
 
70
 
8
 
C for
cytokine assays; the cells were then pulsed with [
 
3
 
H]thymidine,
harvested 16 h later, and counted on a microscintillation counter
(Topcount; Packard Instruments, Meriden, CT). Insulin was re-
combinant human (Humulin R; Eli Lilly), as used for aerosol
treatments. Insulin B chain peptide corresponding to amino acids
9–23 of mouse insulin II (Peptide Express, Fort Collins, CO) was
 
.
 
90% pure, as determined by HPLC analysis. GAD65 was the
recombinant human form expressed with a COOH-terminal hexa-
histidine in a baculovirus system and purified by Ni
 
2
 
1
 
 chelation
affinity chromatography. It was resolved as a single band in SDS-
PAGE, and was endotoxin-free by the quantitative limulus lysate
assay (BioWhittaker, Walkersville, MD).
IL-2, -4, -10, and IFN-
 
g
 
 were measured by ELISAs with mAb
pairs (PharMingen, San Diego, CA); the lower limits of detection
were 62, 16, 16, and 55 pg/ml, respectively. TGF-
 
b
 
1 was mea-
sured with an ELISA kit (Promega, Madison, WI) with a lower
limit of detection of 16 pg/ml.
To detect insulin antibodies, 
 
125
 
I-labeled human insulin (
 
z
 
100,000
cpm; specific activity 120 
 
m
 
Ci/
 
m
 
g) was incubated with or with-
out excess unlabeled insulin (10 
 
m
 
g/ml) in PBS containing a mix-
ture of protease inhibitors and serial log dilutions of mouse serum
for 5 d at 4
 
8
 
C. Complexes were then precipitated with rabbit
anti–mouse globulin antiserum, washed, and counted in a gamma
counter. Positive control sera (guinea pig antiporcine insulin se-
rum, human IDDM sera) maximally precipitated 37–54% of the
total radioactivity. Nonspecific binding, in the presence of excess
unlabeled insulin, was 
 
<
 
3.3%.
 
Adoptive Transfer of Diabetes.
 
Male NOD mice, 6–9 wk old
(16 per group), were irradiated (800 rad) from a cobalt source,
and 3–6 h later, received 2 
 
3
 
 10
 
7
 
 pooled splenocytes from re-
cently diabetic 14–19-wk-old female NOD mice, together with
2 
 
3
 
 10
 
7
 
 splenocytes (or cells fractionated from this number) from
either aerosol insulin- or OVA-treated mice, in 200 
 
m
 
l via the tail
vein. The onset of diabetes was then monitored by measuring
blood glucose starting 2 wk after transfer.
 
Fractionation of Spleen Cell Populations.
 
Spleen cells were treated
with a red cell lysis buffer and resuspended in mouse tonicity PBS.
Total T cells were purified by non-adherence to nylon wool.
CD4 and CD8 cells were positively selected/depleted magneti-
cally with mAbs directly bound to MACS MicroBeads (Miltenyi
Biotec, Bergisch-Gladbach, Germany), according to the manu-
facturer’s protocols, and were counted as viable cells (trypan blue 
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stain negative). Flow cytometry revealed 
 
.
 
95% depletion of
CD4 or CD8 cells, with recoveries of 
 
z
 
80 and 
 
z
 
50%, respec-
tively.
 
gd
 
 T cells were positively selected/depleted by incubating T
cells from aerosol-treated mice first with biotinylated GL3-1A
antibody (PharMingen) and then with streptavidin-MACS Mi-
croBeads, followed by magnetic separation. By flow cytometry,
 
gd
 
 cells were comprised 1–2% of NOD splenic T cells and were
totally depleted with GL3-1A antibody. To purify CD8 
 
gd
 
 T
cells, CD8 T cells were first magnetically selected from total T
cells with anti–CD8-FITC conjugate and anti-FITC Micro-
Beads. The MicroBeads were then released according to the
Miltenyi Biotec protocol, and the CD8 cells were magnetically
separated into 
 
gd
 
-positive and -depleted fractions. Double stain-
ing and FACS
 
Ò
 
 analysis (Becton Dickinson & Co., Mountain
View, CA) demonstrated total depletion of 
 
gd
 
 cells and their re-
covery as a GL3-1A high and low expressing CD8 population.
 
Results and Discussion
 
Diabetes and Insulitis.
 
Aerosol human insulin or OVA
was administered in different schedules to female NOD
mice from 28 d of age, the earliest time at which insulitis is
detectable in our colony, and their incidence of diabetes
and severity of insulitis were subsequently measured.
The incidence of diabetes was only marginally affected
by a single aerosol insulin treatment at 28 d of age, being
72% by 240 d of age, compared to 88% after aerosol OVA.
However, treatment for 3 or 10 consecutive days and then
weekly significantly delayed the onset and reduced the in-
cidence of diabetes. In five separate experiments, diabetes
incidence at 156 d of age was reduced from a median of
47% in OVA-treated mice to 23% in insulin-treated mice;
at 240 d of age, when the cumulative incidence of diabetes
approaches a maximum, the values were 79 and 49%, re-
spectively (
 
P
 
 
 
5
 
 0.005, Kaplan-Meier survival statistic). There
was no difference if the initial treatment was for 3 or 10 d.
In another experiment, in which treatment was given for
10 consecutive days and then weekly, but not started until
49 d of age, when insulitis was well established, aerosol in-
sulin still significantly reduced diabetes incidence at 156 d
from 58 to 25% (
 
P
 
 
 
5
 
 0.001). Insulin treatment was associ-
ated with a significant reduction in the severity of the islet
lesion, as judged by the “insulitis score,” which paralleled
the decrease in diabetes incidence (Table 1). Infiltration of
the salivary glands by lymphoid cells (sialitis), which also
occurs in NOD mice, was unaffected by aerosol insulin.
In the absence of absorption-promoting agents, systemic
uptake of insulin from the nasopharyngeal mucosa in hu-
mans is insignificant (30). In NOD mice, blood glucose
was not altered in the short-term by aerosol insulin (data
not shown). Insulin solutions labeled with 10% Evan’s blue
dye were observed to be deposited in the nasopharynx, tra-
chea, and main bronchial divisions, as well as in the esoph-
agus. While it may be difficult, if not impossible, to avoid
some gastrointestinal exposure after aerosol or intranasal
delivery of soluble protein, delivery into the nasopharynx
alone is sufficient to induce tolerance (18, 31, 32).
 
Table 1.
 
Severity of Insulitis and Frequency of Diabetes in
NOD Mice Treated with Aerosol Protein
 
Protein Insulitis score Diabetes frequency
Insulin 1.2 
 
6
 
 0.98
 
*
 
2/32 (6.3%)
 
‡
 
OVA 2.6 
 
6
 
 0.92 8/32 (25%)
Mice (32 per group) were given either aerosol insulin or OVA for 10
consecutive days and then weekly from 28 d of age. At 105 d of age,
five nondiabetic mice from each group were killed for pancreas histol-
ogy. The insulitis score is expressed as mean 
 
6
 
 SD.
 
*
 
The insulitis score in insulin-treated mice was significantly reduced
(
 
P
 
 
 
,
 
0.01, Mann-Whitney 
 
U
 
 test).
 
‡
 
The diabetes frequency in insulin-treated mice significantly reduced
(
 
P
 
 
 
5
 
 0.04, Fisher’s exact test).
 
Table 2.
 
Proliferative Responses of Splenocytes from
Aerosol-treated Mice
 
Additive
[
 
3
 
H]Thymidine uptake
(cpm, mean 
 
6
 
 SD)
Insulin aerosol OVA aerosol
None 157 
 
6
 
 28
 
*
 
208 
 
6
 
 29
 
i
 
Human insulin (40 
 
m
 
g/ml) 134 
 
6
 
 27 197 
 
6
 
 82
Mouse insulin II B chain
(amino acids 9–23) (40 
 
m
 
g/ml) 169 
 
6
 
 80
 
‡
 
435 
 
6
 
 240
 
¶
 
Human GAD65 (20 
 
m
 
g/ml) 424 
 
6
 
 165
 
§
 
1,381 
 
6
 
 650**
Con A (5 mg/ml) 3,357 6 812 2,960 6 494
Anti-CD3 antibody (10 mg/ml) 2,221 6 533 2,643 6 1,126
Splenocytes from three mice per group were assayed in quadruplicate
in HL-1 serum-free medium. Statistical comparisons (Mann-Whitney
U tests) were between the 12 results for each group.
§ vs * (P 5 0.001), ¶ vs i (P 5 0.016), ** vs i (P 5 0.001), ¶ vs ‡(P 5
0.002), ** vs § (P ,0.001).
Table 3. Cytokine Secretion by Splenocytes from
Aerosol-treated Mice to 40 mg/ml of Mouse Insulin II B Chain 
Peptide (Amino Acids 9–23)
Cytokine Insulin aerosol OVA aerosol
(pg/ml)
IL-2 200 6 15 186 6 27
IFN-g 368 6 71 423 6 31
IL-4 36 6 6 Not detectable
IL-10 222 6 149 Not detectable
TGF-b 293 6 131 162 6 41
Supernatants from the replicate culture wells (Table 2) were sampled af-
ter a 3-d incubation and were assayed for cytokines as described in Ma-
terials and Methods.2170 Aerosol Insulin Induces CD8 gd T Cells That Prevent Diabetes
Immune Responses. We investigated if aerosol insulin
treatment had altered immune responses to insulin. Un-
primed T cell proliferative responses to islet antigens, in-
cluding insulin, have been reported in NOD mice (33), but
have not always been reproducible (34). Proliferative re-
sponses of spleen cells (0.5–2.5 3 106/ml) from either insu-
lin- or OVA-treated mice, 56–105 d old, to human insulin
or OVA (0.2, 2.0, 20, and 40 mg/ml), in different serum-
supplemented or serum-free media varied by less than two-
fold above basal and were usually depressed below basal at
the highest concentration of insulin. Insulin at high con-
centrations has been reported to inhibit T cell responses
Figure 1. Aerosol insulin induces CD8 T cells that suppress the transfer of diabetes. 6–9-wk-old NOD male mice (n 5 16 per group) were injected
with pooled splenocytes from recently diabetic 14–19-wk-old females, together with either unfractionated (A) or fractionated (B–E) splenocytes from
aerosol insulin– or OVA-treated NOD females, and their incidence of diabetes was subsequently monitored. In the experiment shown, aerosol donor
mice had been treated for 10 consecutive days and then weekly from 49 d of age, and were normoglycemic when killed at 156 d of age.2171 Harrison et al.
(35). In contrast, in the OVA-treated control mice, but not
the insulin-treated mice, responses to insulin B chain pep-
tide amino acids 9–23, a dominant epitope for NOD
mouse islet–derived T cell clones (15), were significant
(Table 2). Furthermore, OVA mice had significantly higher
responses than insulin mice to human GAD65, which was
previously reported to stimulate splenic T cells in NOD
mice (33). In mice from both treatment groups, prolifera-
tive responses to non–antigen-specific stimulation by Con
A or the T cell receptor CD3 mAb, 145-2C11 were similar
(Table 2) and no different to untreated mice (not shown),
indicating that aerosol treatment did not cause general im-
munosuppression. IL-2, IFN-g, and TGF-b1 secretion in
response to insulin B chain amino acids 9–23 were not sig-
nificantly different between insulin- and OVA-treated mice;
however, the levels of IL-4 and particularly IL-10 were
higher in the wells from insulin-treated mice (Table 3).
Insulin antibodies were measured by a standard immu-
noprecipitation assay with sera (n 5 12 per group) from in-
sulin- and OVA-treated mice aged 70–105 d. Precipitation
of 125I-insulin radioactivity by antibodies in sera from insu-
lin-treated mice (12.7 6 3.6%; mean precipitated cpm 6
SD) was significantly higher (P ,0.01, Mann-Whitney U test)
than in OVA-treated mice (6.9 6 2.6%). This increase in
the “level” of insulin antibodies after aerosol insulin, to-
gether with the suppression of T cell proliferation and the
increase in IL-4 and IL-10 responses to the insulin B chain
peptide, is consistent with the phenomenon of immune de-
viation, as described after oral myelin basic protein in Lewis
rats (16) and intranasal GAD peptides in NOD mice (22).
b cell destruction within the DTH lesion of IDDM is an
example of a Th1-mediated process (1, 2), whose inhibi-
tion by aerosol insulin might be expected to shift the Th1/
Th2 balance towards Th2 in response to key islet antigens.
Defective suppressor T cell function has been postulated to
shift the balance towards Th1 in IDDM (2). It seems un-
likely that the reduced T cell proliferative response to GAD
could reflect “bystander” suppression caused by the secre-
tion of the Th2 cytokines IL-4 and IL-10 (16) by insulin
aerosol–induced regulatory cells because, apart from an ab-
sence of added insulin in the cultures with GAD, responses
to Con A and anti-CD3 were not impaired. A direct expla-
nation is that the reduced response to GAD reflects the
protective effect of aerosol insulin on insulitis and b cell
destruction. This implies that at least some GAD immunity
is secondary, and that immunity to (pro)insulin may have a
more proximal role in b cell destruction. Although NOD
mouse T cell responses to human GAD65 have been re-
ported to be stronger and to appear earlier than those to
native human insulin (33), we have recently shown (36)
that the transgenic expression of mouse proinsulin II in
NOD mouse APCs completely prevents insulitis and dia-
betes.
Regulatory CD8 gd T Cells. As mucosal tolerance has
been associated with the appearance of “regulatory” cells in
the spleen (16, 18, 20–23), we asked if aerosol insulin–
induced regulatory cells that could inhibit the adoptive
transfer of diabetes by pathogenic effector T cells. In the
classic adoptive transfer model (37; see Fig. 3), spleen cells
from diabetic NOD female mice transferred intravenously
to young, irradiated, nondiabetic, syngenic male or female
recipients cause clinical diabetes in the majority within 4
wk. When we coinjected 2 3 107 spleen cells from older,
diabetic mice with an equal number of spleen cells from
aerosol OVA mice, the majority of young recipients devel-
oped diabetes within 4–5 wk; in contrast, after coinjection
with spleen cells from aerosol insulin mice, only a minority
developed diabetes (Fig. 1 A). Diabetes incidence was sup-
pressed by >75% in six separate experiments with either
splenocytes or nylon wool–nonadherent splenocytes (en-
riched for T cells) from aerosol insulin mice.
Spleen cells were then fractionated to identify the regu-
latory cells responsible for the suppression of diabetes trans-
fer. Depletion and positive selection of CD4 and CD8 cells
clearly showed that CD8 cells were wholly responsible for
the suppression of transfer (Fig. 1, B–E). Depletion of CD4
cells did not alter the ability of residual spleen cells from
aerosol insulin mice to suppress transfer (Fig. 1 B), and pos-
itively selected CD4 cells did not suppress transfer (Fig. 1 C).
On the other hand, there was no suppression by CD8-
depleted spleen cells from aerosol insulin mice (Fig. 1 D),
whereas positively selected CD8 cells suppressed transfer
(Fig. 1 E). The partial suppression by positively selected
CD8 cells, in contrast to the rapid development of diabetes
after their depletion, is probably caused by inefficient re-
covery of CD8 cells; in this experiment, 7 3 105 purified
CD8 cells were coinjected into each recipient with 2 3 107
spleen cells from diabetic mice.
T cells bearing gd receptors have been shown to have an
immunoregulatory role (24–29). Interestingly, it has been
reported that total peripheral blood gd cells decrease con-
comitantly with the loss of b cell function in humans with
subclinical IDDM (38). McMenamin et al. (23) found that
small numbers of gd T cells could adoptively transfer the
suppression of OVA-specific IgE responses induced in mice
by repeated inhalation of OVA. To determine if the sup-
pression of diabetes transfer that we observed was caused by
gd T cells, we fractionated spleen cells with the anti-gd T
cell mAb GL3-1A (39). Depletion of gd T cells, like that of
CD8 cells, completely abrogated the ability of nylon wool–
nonadherent spleen cells from insulin aerosol–treated mice
to suppress the adoptive transfer of diabetes (Fig. 2 A).
Conversely, relatively small numbers of gd T cells from in-
sulin aerosol–treated mice could suppress transfer. Diabetes
incidence after transfer was decreased by 50% for at least 70 d
when 1.4 3 105 gd T cells were coinjected with 2 3 107
spleen cells from diabetic mice (Fig. 2 A). The splenic CD8
and gd T cells that suppressed diabetes transfer were one
and the same, and not two interdependent populations.
Thus, the ability of CD8 cells from insulin aerosol–treated
mice to suppress transfer was abolished if they were first de-
pleted of gd T cells, whereas small numbers of gd cells pu-
rified from the CD8 cells prevented transfer (Fig. 2 B). A
summary of the results from 11 different cotransfer experi-
ments is presented in Fig 3.
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antibody constitute 1.6–2.4% of total and z1% of CD81
T cells in the spleens of 12–16-wk-old female NOD mice.
These values were no different between groups of mice
treated with insulin or OVA aerosol. However, because of
their low abundance distinct subpopulations of antigen-
specific CD8 gd T cells would be difficult to distinguish
this way. The higher protection with fractionated cells,
e.g., sequentially purified CD8 gd cells (Fig. 3), is quantita-
tive and reflects their higher absolute number relative to
that in unfractionated cells.
Aerosol inhalation as a mode of insulin delivery to the
mucosa was as effective as oral insulin (20, 21) in reducing
diabetes incidence in the NOD mouse. The fact that it was
therapeutic after the onset of insulitis is especially relevant to
the prevention of IDDM in at-risk humans with subclinical
disease in whom the presence of circulating islet antigen–
reactive antibodies and T cells is taken to reflect underlying
insulitis. Indeed, compared to humans with recently diag-
nosed IDDM, NOD mice have more intense insulitis and
the majority of females progress to diabetes (1, 2, 4). Aero-
sol insulin had no obvious metabolic effect, but it induced a
population of regulatory CD8 gd T cells, small numbers of
which suppressed the ability of pathogenic effector T cells
to adoptively transfer diabetes. These antigen-induced “sup-
pressor” T cells that are protective against cell-mediated au-
toimmune pathology have not been described previously.
The striking potency of these cells, unparalleled in “infec-
tious suppression,” was noted by McMenamin et al. (23) in
their experimental model of OVA aerosol–induced sup-
pression of OVA-specific IgE and T cell responses, and im-
plies they have the capacity to expand in vivo after transfer.
The ability of CD8 gd T cells to suppress, on the one hand,
cell-mediated autoimmune disease in NOD mice and, on
the other, an “allergic” response to exogenous OVA in
C57Bl mice (23) or Brown Norway rats (40) seems para-
doxical within the framework of the Th1–Th2 paradigm.
However, the overriding consideration is that mucosa-medi-
ated tolerance is manifest in genetically susceptible strains
by suppression of both DTH and IgE responses (18); either
the strict dichotomy of the Th1–Th2 paradigm may not
apply and/or there may be rodent strain variations in mu-
cosa-mediated tolerance responses that reflect differences in
Th1–Th2 balance. It would be interesting to determine if
OVA aerosol induces CD8 gd T cells that suppress OVA-
specific IgE responses in NOD mice.
Oral tolerance has been associated with a decrease in cel-
lular and sometimes an increase in humoral antigen-specific
Figure 2. Aerosol insulin induces CD8 gd T cells that suppress transfer
of diabetes. Young male NOD mice were coinjected with “diabetic”
splenocytes (2 3 107) and total or fractionated splenic T cells from aero-
sol-treated mice, as described in the legend to Fig. 1. The numbers of
fractionated cells injected were, (A) z107 total T cells and, from aerosol
insulin mice, z107 gd-depleted T cells or 1.4 3 105 gd T cells and, (B)
from aerosol insulin mice, z107 total T cells, 2 3 106 CD8 T cells, 2 3
106 gd-depleted CD8 T cells, or 1.5 3 105 CD8 gd1 T cells.
Figure 3. Adoptive transfer of diabetes is suppressed by CD8 gd T cells
induced by aerosol insulin: summary of 11 experiments.2173 Harrison et al.
immunity, and with either CD8 or CD4 T cells that se-
crete, respectively, TGF-b or IL-4, IL-10, and TGF-b1
(16). However, these regulatory cells have not been identi-
fied as bearing gd receptors. In NOD mice, oral tolerance
to insulin was attributed to regulatory CD4 T cells (21).
We have shown that CD8 gd T cells account entirely for
the regulatory cells induced by aerosol insulin. This finding
raises the possibility that the mechanisms and regulatory
cells that mediate mucosal tolerance in the upper airways
and gut are different. Experiments are in progress to iden-
tify the origin, fate, antigen specificity, and exact mode of
action of insulin aerosol–induced regulatory CD8 gd T cells.
Total gd T cells in the spleens of NOD female mice de-
crease with age similarly to BALB/c mice (41), but the role
of specific gd T cells in the natural history of diabetes in the
NOD mouse remains to be defined. In subclinical IDDM
subjects, a decrease in the number of peripheral blood
Vg9Vd2 T cells signaled loss of b cell function and progres-
sion to clinical diabetes (38). We suggest, therefore, that
peripheral regulatory CD8 gd T cells could have a critical
role in determining the natural history of islet autoimmu-
nity. Moreover, the induction of these regulatory cells by
aerosol delivery of insulin (or other islet antigens) has im-
plications for the prevention of clinical diabetes in at-risk
humans.
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